Vascular Disrupting Agents (VDAs) Market By Type (Small Molecules VDAs and Ligand directed VDAs); By Development Phase (Preclinical, Phase I, Phase II, Phase III); By Therapeutic Indication (Melanoma, Non-small Cell lung Cancer, Prostate Cancer, Renal and Ovarian Cancer, Glioblastoma, Others); By Therapy Type (Monotherapy, Combination Therapy); By Route of Administration (Intravenous, Oral and Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia(Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia) Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2029

Report ID :AMI-1071 | Category : Healthcare | Published Date : February, 2022 | Pages : 420 | Format :PDF